Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells

Ankur Sharma, Clay E S Comstock, Erik S. Knudsen, Khanh H. Cao, Janet K. Hess-Wilson, Lisa M. Morey, Jason Barrera, Karen E. Knudsen

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The retinoblastoma tumor suppressor protein (RB), a critical mediator of cell cycle progression, is functionally inactivated in the majority of human cancers, including prostatic adenocarcinoma. The importance of RB tumor suppressor function in this disease is evident because 25% to 50% of prostatic adenocarcinomas harbor aberrations in RB pathway. However, no previous studies challenged the consequence of RB inactivation on tumor cell proliferation or therapeutic response. Here, we show that RB depletion facilitates deregulation of specific E2F target genes, but does not confer a significant proliferative advantage in the presence of androgen. However, RB-deficient cells failed to elicit a cytostatic response (compared with RB proficient isogenic controls) when challenged with androgen ablation, AR antagonist, or combined androgen blockade. These data indicate that RB deficiency can facilitate bypass of first-line hormonal therapies used to treat prostate cancer. Given the established effect of RB on DNA damage checkpoints, these studies were then extended to determine the impact of RB depletion on the response to cytotoxic agents used to treat advanced disease. In this context, RB-deficient prostate cancer cells showed enhanced susceptibility to cell death induced by only a selected subset of cytotoxic agents (antimicrotubule agents and a topoisomerase inhibitor). Combined, these data indicate that RB depletion dramatically alters the cellular response to therapeutic intervention in prostate cancer cells and suggest that RB status could potentially be developed as a marker for effectively directing therapy.

Original languageEnglish (US)
Pages (from-to)6192-6203
Number of pages12
JournalCancer Research
Volume67
Issue number13
DOIs
StatePublished - Jul 1 2007

Fingerprint

Retinoblastoma
Prostatic Neoplasms
Androgens
Cytotoxins
Neoplasms
Adenocarcinoma
Topoisomerase Inhibitors
Tumor Suppressor Proteins
Retinoblastoma Protein
Cytostatic Agents
Therapeutics
DNA Damage
Cell Cycle
Cell Death
Cell Proliferation
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sharma, A., Comstock, C. E. S., Knudsen, E. S., Cao, K. H., Hess-Wilson, J. K., Morey, L. M., ... Knudsen, K. E. (2007). Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Research, 67(13), 6192-6203. https://doi.org/10.1158/0008-5472.CAN-06-4424

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. / Sharma, Ankur; Comstock, Clay E S; Knudsen, Erik S.; Cao, Khanh H.; Hess-Wilson, Janet K.; Morey, Lisa M.; Barrera, Jason; Knudsen, Karen E.

In: Cancer Research, Vol. 67, No. 13, 01.07.2007, p. 6192-6203.

Research output: Contribution to journalArticle

Sharma, A, Comstock, CES, Knudsen, ES, Cao, KH, Hess-Wilson, JK, Morey, LM, Barrera, J & Knudsen, KE 2007, 'Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells', Cancer Research, vol. 67, no. 13, pp. 6192-6203. https://doi.org/10.1158/0008-5472.CAN-06-4424
Sharma, Ankur ; Comstock, Clay E S ; Knudsen, Erik S. ; Cao, Khanh H. ; Hess-Wilson, Janet K. ; Morey, Lisa M. ; Barrera, Jason ; Knudsen, Karen E. / Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. In: Cancer Research. 2007 ; Vol. 67, No. 13. pp. 6192-6203.
@article{f847107586ef468b8795591a6ed02b44,
title = "Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells",
abstract = "The retinoblastoma tumor suppressor protein (RB), a critical mediator of cell cycle progression, is functionally inactivated in the majority of human cancers, including prostatic adenocarcinoma. The importance of RB tumor suppressor function in this disease is evident because 25{\%} to 50{\%} of prostatic adenocarcinomas harbor aberrations in RB pathway. However, no previous studies challenged the consequence of RB inactivation on tumor cell proliferation or therapeutic response. Here, we show that RB depletion facilitates deregulation of specific E2F target genes, but does not confer a significant proliferative advantage in the presence of androgen. However, RB-deficient cells failed to elicit a cytostatic response (compared with RB proficient isogenic controls) when challenged with androgen ablation, AR antagonist, or combined androgen blockade. These data indicate that RB deficiency can facilitate bypass of first-line hormonal therapies used to treat prostate cancer. Given the established effect of RB on DNA damage checkpoints, these studies were then extended to determine the impact of RB depletion on the response to cytotoxic agents used to treat advanced disease. In this context, RB-deficient prostate cancer cells showed enhanced susceptibility to cell death induced by only a selected subset of cytotoxic agents (antimicrotubule agents and a topoisomerase inhibitor). Combined, these data indicate that RB depletion dramatically alters the cellular response to therapeutic intervention in prostate cancer cells and suggest that RB status could potentially be developed as a marker for effectively directing therapy.",
author = "Ankur Sharma and Comstock, {Clay E S} and Knudsen, {Erik S.} and Cao, {Khanh H.} and Hess-Wilson, {Janet K.} and Morey, {Lisa M.} and Jason Barrera and Knudsen, {Karen E.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-06-4424",
language = "English (US)",
volume = "67",
pages = "6192--6203",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells

AU - Sharma, Ankur

AU - Comstock, Clay E S

AU - Knudsen, Erik S.

AU - Cao, Khanh H.

AU - Hess-Wilson, Janet K.

AU - Morey, Lisa M.

AU - Barrera, Jason

AU - Knudsen, Karen E.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - The retinoblastoma tumor suppressor protein (RB), a critical mediator of cell cycle progression, is functionally inactivated in the majority of human cancers, including prostatic adenocarcinoma. The importance of RB tumor suppressor function in this disease is evident because 25% to 50% of prostatic adenocarcinomas harbor aberrations in RB pathway. However, no previous studies challenged the consequence of RB inactivation on tumor cell proliferation or therapeutic response. Here, we show that RB depletion facilitates deregulation of specific E2F target genes, but does not confer a significant proliferative advantage in the presence of androgen. However, RB-deficient cells failed to elicit a cytostatic response (compared with RB proficient isogenic controls) when challenged with androgen ablation, AR antagonist, or combined androgen blockade. These data indicate that RB deficiency can facilitate bypass of first-line hormonal therapies used to treat prostate cancer. Given the established effect of RB on DNA damage checkpoints, these studies were then extended to determine the impact of RB depletion on the response to cytotoxic agents used to treat advanced disease. In this context, RB-deficient prostate cancer cells showed enhanced susceptibility to cell death induced by only a selected subset of cytotoxic agents (antimicrotubule agents and a topoisomerase inhibitor). Combined, these data indicate that RB depletion dramatically alters the cellular response to therapeutic intervention in prostate cancer cells and suggest that RB status could potentially be developed as a marker for effectively directing therapy.

AB - The retinoblastoma tumor suppressor protein (RB), a critical mediator of cell cycle progression, is functionally inactivated in the majority of human cancers, including prostatic adenocarcinoma. The importance of RB tumor suppressor function in this disease is evident because 25% to 50% of prostatic adenocarcinomas harbor aberrations in RB pathway. However, no previous studies challenged the consequence of RB inactivation on tumor cell proliferation or therapeutic response. Here, we show that RB depletion facilitates deregulation of specific E2F target genes, but does not confer a significant proliferative advantage in the presence of androgen. However, RB-deficient cells failed to elicit a cytostatic response (compared with RB proficient isogenic controls) when challenged with androgen ablation, AR antagonist, or combined androgen blockade. These data indicate that RB deficiency can facilitate bypass of first-line hormonal therapies used to treat prostate cancer. Given the established effect of RB on DNA damage checkpoints, these studies were then extended to determine the impact of RB depletion on the response to cytotoxic agents used to treat advanced disease. In this context, RB-deficient prostate cancer cells showed enhanced susceptibility to cell death induced by only a selected subset of cytotoxic agents (antimicrotubule agents and a topoisomerase inhibitor). Combined, these data indicate that RB depletion dramatically alters the cellular response to therapeutic intervention in prostate cancer cells and suggest that RB status could potentially be developed as a marker for effectively directing therapy.

UR - http://www.scopus.com/inward/record.url?scp=34447121974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447121974&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-4424

DO - 10.1158/0008-5472.CAN-06-4424

M3 - Article

C2 - 17616676

AN - SCOPUS:34447121974

VL - 67

SP - 6192

EP - 6203

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -